Exploratory experiment designed to discover new patterns targeting ACSL1, PPARγ, CYP7A1, SCD1, ACLY, SREBF1, CPT1A, ACC1, APOE4 in C57BL/6J mouse liver and epididymal fat tissue. Primary outcome: gene expression changes in metabolic pathways and microRNA regulation
This comprehensive gene expression study utilized RNA sequencing and metabolomics to investigate the molecular mechanisms underlying myricanol's lipid-lowering effects. The analysis revealed that myricanol treatment significantly altered the expression of key metabolic genes in liver tissue, including upregulation of ACSL1, PPARγ, CYP7A1, SCD1, ACLY, and SREBF1. In epididymal fat tissue, myricanol increased expression of PPARγ, CPT1A, ACC1, ACSL1, APOE4, and SREBF1. The study also identified regulation of specific microRNAs including miR-203b-3p, miR-205-5p, and miR-184-3p. Additionally, pathway analysis revealed modulation of the interferon (IFN) pathway and IFN-stimulated genes. The multi-omics approach provided systems-level insight into how myricanol orchestrates metabolic reprogramming to achieve its therapeutic effects, demonstrating coordinate regulation of lipid synthesis, oxidation, and transport pathways.
RNA sequencing for transcriptome analysis, metabolomics for metabolite profiling, pathway enrichment analysis for functional annotation
Upregulation of beneficial metabolic genes, modulation of lipid metabolism pathways, altered microRNA expression profiles
Significant differential expression of target genes, pathway enrichment in lipid metabolism, coordinated regulation of metabolic networks
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.